Synaptogenix Inc (SNPX)

[SF Wolf]

10K has been released:

The improvement in "non-memantine patients in the Completers Group...showed an SIB improvement of 6.24 for an overall treatment of 6.36 from baseline (p=0.0488)" is the key to understanding the recent increase in enterprise value of Neurotrope.

From page 4:

Additional analyses compared 20 µg dose patients who were on baseline therapy of Aricept vs. patients off Aricept. No significant differences were observed. Another analysis compared the 20 µg dose patients who were on or off baseline therapy of memantine. Post-hoc analysis comparing SIB scores in non-memantine versus memantine patients found the following:


·
At week 15, non-memantine patients in the mITT Group treated with 20 µg (n=14) showed an SIB improvement of 5.88, while the placebo patients (n=11) showed a decline in their SIB scores of - 0.05 for an overall treatment ? of 5.93 from baseline ( p =0.0576).


·
At week 15, non-memantine patients in the Completers Group treated with 20 µg (n=14) showed an SIB improvement of 6.24, while the placebo patients (n=11) showed a decline in their SIB scores of - 0.12 for an overall treatment of 6.36 from baseline (p=0.0488).


·
Patients taking memantine as background therapy in the 20 µg (n=20) and control (n=22) groups showed no improvement in SIB scores.

Memantine, an NMDA receptor antagonist, is marketed under the brand names Namenda®, Namenda® XR, and Namzaric® (a combination of memantine and donepezil) for the treatment of dementia in patients with moderate-to-severe AD. It has been shown to delay cognitive decline and help reduce disease symptoms.

Neurotrope is planning a replication trial for the safe, effective 20 µg dose protocol for advanced AD patients not taking memantine as background therapy to evaluate improvements in SIB scores with an increased number of patients. We are in discussions with investigators at leading academic institutions to collaborate on the design and conduct of the next trial, which is expected to begin in the first half of 2018.

To the extent resources permit, we intend to pursue development of selected technology platforms with indications – such as Fragile X disease - related to the treatment of AD and other neurodegenerative disorders based on our current licensed technology and / or technologies available from third party licensors or collaborators.

https://seekingalpha.com/filing/3924750?app=1